Newron Receives EUR11.3m Milestone Payments

US Approval of Xadago for the treatment of Parkinson’s disease

12-May-2017 - Newron Pharmaceuticals S.p.A. announced the receipt of milestone payments linked to the approval of its lead compound Xadago® (safinamide) for the treatment of Parkinson’s disease by the US Food and Drug Administration. The payments were made by Newron’s partner Zambon, who holds the rights to ...

Rett syndrome: Newron Receives FDA Orphan Drug Designation for Sarizotan

15-Jul-2015 - Newron Pharmaceuticals S.p.A. announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Newron’s New Chemical Entity (NCE) sarizotan for treatment of Rett syndrome. Newron also recently announced that it received a positive opinion from the Committee for ...

Merck Returns Rights for Safinamide to Newron

24-Oct-2011 - Merck KGaA announced that it has decided to return all rights for safinamide to Newron Pharmaceuticals S.p.A. Merck had acquired exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson’s disease and other therapeutic applications, pursuant to its agreement ...

Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Nervous System Drug Development

29-Sep-2011 - Biotie Therapies Corp. and Newron Pharmaceuticals S.p.A. announced that they have signed an agreement for Biotie to acquire Newron in a transaction valued at EUR 45 million. The Transaction is still subject inter alia to the approval by the EGM of Newron expected to be convened at the end of ...

Merck Completes Patient Enrollment in MOTION, a Phase III Pivotal Clinical Trial of Safinamide in Early Parkinson’s Disease

Study will evaluate safety and efficacy of safinamide as add-on to dopamine agonist therapy in early Parkinson’s disease

01-Jul-2011 - Merck KGaA and its partner Newron Pharmaceuticals S.p.A. announced that patient enrollment has been completed in the MOTION1 study. This randomized, double-blind, placebo-controlled, international phase III pivotal trial is designed to evaluate the efficacy and safety of two dose regimens of ...

Merck KGaA: Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson’s Disease

05-Nov-2010 - Merck KGaA and its partner Newron Pharmaceuticals S.p.A. announced the top-line results of an 18-month, double-blind, placebo-controlled extension study (study 018) of a previously completed and reported 6-month Phase III study (study 016) of safinamide. The objective of this extension study was ...

Newron Pharmaceuticals Raises EUR 30 Million

24-Feb-2005 - Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced the raising of EUR 30 million (fully committed), out of which EUR 23 million closed already. The remaining EUR 7 million will remain open to additional interested parties for a few weeks. HBM ...

Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome

12-Jan-2005 - Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced that treatment with its investigational new drug, safinamide, resulted in a significant improvement in all efficacy parameters studied when administered to patients with Restless Legs ...